It’s worth noting that pioglitazone, a member of the thiazolidinedione class and a ligand for PPARγ, has been recognized for its beneficial effects on macrovascular complications in diabetes and has shown promise in experimental diabetic neuropathy [71]. Here, PPARG is linked to diabetic neuropathy.